Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio
Everest Medicines (HKG: 1952) announced a definitive agreement to acquire 100% of the equity interests...
Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration...
GSK’s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio
GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China’s National Medical Products Administration (NMPA) has granted...
Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development
The Beijing Municipal Medical Insurance Bureau, in coordination with nine other government bureaus, has released...
Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China’s National...
Gan & Lee Pharmaceuticals Launches China’s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer
Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China’s National...
Amgen’s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response
Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating...
China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized
The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications...
Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform
Genesis MedTech, a Singapore-based medical device innovator, has acquired a controlling stake in Nanjing TUGE...
Sansure Biotech to Acquire WWHS Biotech, Gaining Exclusive Infrared Fluorescence Platform for Full-Scenario IVD Expansion
Sansure Biotech Inc. (SHA: 688289), a leading Chinese in vitro diagnostics (IVD) company, has entered...
Conmind Medical Raises $29M in Series C to Advance Brain-Computer Interface and Cardio-Cerebral Integrated Care Platform
Conmind Medical, a China-based brain science and medical technology platform, has secured RMB 200 million...
Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software
Siemens Healthineers AG (ETR: SHL) has entered into a strategic collaboration with Ruijin Hospital, a...
Zhuhai Rundu’s Higenamine Receives NMPA Approval as China’s First Category 1 Cardiac Stress Test Agent
China’s National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1...
Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China’s...
Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline
Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong...
Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
Youcare Pharmaceutical Group (SHA: 688658) announced that its YKYY018 aerosolized inhalation formulation has received approval...
Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline
Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the...
Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen
Merck & Co., Inc. (MSD, NYSE: MRK) announced that the European Commission has granted marketing...
Merck Launches Pivotal Phase 2b/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment
Merck & Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b/3...
Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline
Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253...